

TOM DAVIS, VIRGINIA,  
CHAIRMAN

CHRISTOPHER SHAYS, CONNECTICUT  
DAN BURTON, INDIANA  
ILEANA ROS-LEHTINEN, FLORIDA  
JOHN M. McHUGH, NEW YORK  
JOHN L. MICA, FLORIDA  
GIL GUTKNECHT, MINNESOTA  
MARK E. SOUDER, INDIANA  
STEVEN C. LATOURETTE, OHIO  
TODD RUSSELL PLATTS, PENNSYLVANIA  
CHRIS CANNON, UTAH  
JOHN J. DUNCAN, JR., TENNESSEE  
CANDICE MILLER, MICHIGAN  
MICHAEL R. TURNER, OHIO  
DARRELL ISSA, CALIFORNIA  
JON C. PORTER, NEVADA  
KENNY MARCHANT, TEXAS  
LYNN A. WESTMORELAND, GEORGIA  
PATRICK T. McHENRY, NORTH CAROLINA  
CHARLES W. DENT, PENNSYLVANIA  
VIRGINIA FOXX, NORTH CAROLINA  
JEAN SCHMIDT, OHIO  
BRIAN P. BILBRAY, CALIFORNIA

ONE HUNDRED NINTH CONGRESS

# Congress of the United States

## House of Representatives

COMMITTEE ON GOVERNMENT REFORM

2157 RAYBURN HOUSE OFFICE BUILDING

WASHINGTON, DC 20515-6143

MAJORITY (202) 225-5074  
FACSIMILE (202) 225-3974  
MINORITY (202) 225-5051  
TTY (202) 225-6852

<http://reform.house.gov>

December 7, 2006

HENRY A. WAXMAN, CALIFORNIA,  
RANKING MINORITY MEMBER

TOM LANTOS, CALIFORNIA  
MAJOR R. OWENS, NEW YORK  
EDOLPHUS TOWNS, NEW YORK  
PAUL E. KANJORSKI, PENNSYLVANIA  
CAROLYN B. MALONEY, NEW YORK  
ELIJAH E. CUMMINGS, MARYLAND  
DENNIS J. KUCINICH, OHIO  
DANNY K. DAVIS, ILLINOIS  
WM. LACY CLAY, MISSOURI  
DIANE E. WATSON, CALIFORNIA  
STEPHEN F. LYNCH, MASSACHUSETTS  
CHRIS VAN HOLLEN, MARYLAND  
LINDA T. SANCHEZ, CALIFORNIA  
C.A. DUTCH RUPPERSBERGER,  
MARYLAND  
BRIAN HIGGINS, NEW YORK  
ELEANOR HOLMES NORTON,  
DISTRICT OF COLUMBIA

BERNARD SANDERS, VERMONT,  
INDEPENDENT

Andrew C. von Eschenbach, M.D.  
Acting Commissioner  
U.S. Food and Drug Administration  
U.S. Department of Health and Human Services  
5600 Fishers Lane, Room 15-47  
Rockville, MD 20857

Dear Dr. von Eschenbach:

I am writing to follow up on my previous letters to you regarding the recent surge in the use of phenylephrine oral nasal decongestants, which have been marketed as alternatives to the pseudoephedrine products now exclusively sold behind the counter pursuant to anti-methamphetamine provisions included in the 2006 reauthorization of the Patriot Act.<sup>1</sup> In my September 22 and October 23 letters, I highlighted the fact that Schering Plough had recently conducted and completed a study comparing phenylephrine to both placebo and to pseudoephedrine.<sup>2</sup> Since the writing of those letters, the company has made the results of the study public,<sup>3</sup> and, I understand, provided these results to you as well.

---

<sup>1</sup> USA PATRIOT Improvement and Reauthorization Act of 2005, Pub. L. No. 109-177, enacted March 9, 2006. The Combat Methamphetamine Epidemic Act of 2005 (H.R. 3889) was passed as Title VII of the Patriot Act.

<sup>2</sup> U.S. National Institutes of Health, ClinicalTrials.gov, "The Effects of Phenylephrine Compared With Those of Placebo and Pseudoephedrine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis (SAR) (Study P04579)" (online at: [www.clinicaltrials.gov/ct/show/NCT00276016;jsessionid=1B43B1BF395CA89630495B0A166321ED?order=1](http://www.clinicaltrials.gov/ct/show/NCT00276016;jsessionid=1B43B1BF395CA89630495B0A166321ED?order=1)) (accessed on October 17, 2006).

<sup>3</sup> PhRMA Clinicalstudyresults.org, *Protocol P04579: Crossover Study of the Decongestant Effect of Phenylephrine Compared With Placebo and Pseudoephedrine as Active Control in SAR Subjects Exposed to Pollen in the Vienna Challenge Chamber* (online at: [www.clinicalstudyresults.org/drugdetails/?company\\_id=11&inn\\_name\\_id=394&sort=c.company\\_name&page=1&drug\\_id=1683](http://www.clinicalstudyresults.org/drugdetails/?company_id=11&inn_name_id=394&sort=c.company_name&page=1&drug_id=1683))

Andrew C. von Eschenbach, M.D.  
December 7, 2006  
Page 2


As you now know, the Schering study found that phenylephrine at the FDA-monograph dose was not significantly different than placebo and was significantly less effective than pseudoephedrine in decreasing nasal congestion. Now is the time for FDA to reexamine whether phenylephrine works.

In response to my previous letters, you have indicated that you would not convene a meeting of the Nonprescription Drugs Advisory Committee to examine the effectiveness of phenylephrine because you were unaware of any data contradicting that considered by the advisory panel originally convened in 1976 to evaluate phenylephrine. The Schering study provides strong evidence that the conclusions of the original panel need to be re-examined. FDA, along with the input of the Nonprescription Drugs Advisory Committee, should promptly make a serious scientific inquiry into whether there is an effective, and safe, dose of phenylephrine.

FDA must ensure Americans that it has done everything in its power to prevent them from needlessly wasting their hard-earned dollars on medicines that do not work.

Please respond to this letter no later than December 22, 2006.

Sincerely,

A handwritten signature in dark ink, appearing to read "Henry A. Waxman", with a horizontal line extending to the right.

Henry A. Waxman  
Ranking Minority Member